Market revenue in 2023 | USD 34.5 million |
Market revenue in 2030 | USD 59.4 million |
Growth rate | 8.1% (CAGR from 2023 to 2030) |
Largest segment | Bioavailability & bioequivalence studies |
Fastest growing segment | Bioavailability & Bioequivalence Studies |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Bioavailability & Bioequivalence Studies, Pharmacokinetics, Pharmacodynamics, Other test type |
Key market players worldwide | IQVIA Holdings Inc, Labcorp Holdings Inc, Thermo Fisher Scientific Inc, Pharmaron Beijing Co Ltd Ordinary Shares - Class H, Charles River Laboratories International Inc, Syneos Health, Intertek Group PLC |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell & gene therapy bioanalytical testing services market will help companies and investors design strategic landscapes.
Bioavailability & bioequivalence studies was the largest segment with a revenue share of 35.36% in 2023. Horizon Databook has segmented the China cell & gene therapy bioanalytical testing services market based on bioavailability & bioequivalence studies, pharmacokinetics, pharmacodynamics, other test type covering the revenue growth of each sub-segment from 2018 to 2030.
China has been actively investing and advancing its capabilities in cell & gene therapy. The country has a rapidly growing biotechnology & pharmaceutical sector, and it has shown significant interest and progress in this field. Gene therapies, such as Chimeric Antigen Receptor (CAR) T-cell immunotherapy, have been reported to be effective treatments for diseases such as cancer and HIV infection.
China is home to the third-highest number of gene therapy clinical trials worldwide. According to an article published by The Lancet Hematology journal in December 2022, in China, approximately 200,000 babies are born each year with genetic disorders, of which 22% are caused by monogenic mutations.
The four most common genetic disorders are birth defects, endocrine or metabolic diseases, nervous system diseases, and blood system diseases. China has become a major hub for clinical trials in cell and gene therapy. The country's large population and relatively streamlined regulatory processes have made it an attractive location for conducting clinical research in this area.
Horizon Databook provides a detailed overview of country-level data and insights on the China cell & gene therapy bioanalytical testing services market , including forecasts for subscribers. This country databook contains high-level insights into China cell & gene therapy bioanalytical testing services market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account